Journal Updates
eMediNexus Coverage from: 
Lanadelumab gets marketing approval hereditary angioedema
eMediNexus,  29 October 2018
remove_red_eye 654 Views
#Dermatology #Pharmacist

0 Read Comments                

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted marketing approval to lanadelumab as the first monoclonal antibody for preventing recurrent attacks of the rare hereditary angioedema.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now